Lipoprotein-associated phospholipase A2 (Lp-PLA2) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (Lp-PLA2 + HMGCR)

The combination of Lipoprotein-associated phospholipase A2 (Lp-PLA2) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) represents a dual-target strategy for addressing both the lipid and inflammatory components of atherosclerotic cardiovascular disease. HMGCR is the rate-limiting enzyme in the mevalonate pathway, responsible for endogenous cholesterol production; its inhibition by statins is the primary method for lowering low-density lipoprotein cholesterol (LDL-C) and reducing major adverse cardiovascular events (StatPearls, 2023). Lp-PLA2, also known as platelet-activating factor acetylhydrolase, is an enzyme that circulates primarily on LDL particles and hydrolyzes oxidized phospholipids within the arterial wall to produce pro-inflammatory mediators like lysophosphatidylcholine (UniProt Q13093). While statins effectively lower LDL-C and indirectly reduce the circulating mass of Lp-PLA2, direct inhibition of Lp-PLA2 was hypothesized to provide incremental benefit by specifically reducing plaque-level inflammation (Tsimikas et al., 2009). However, large-scale Phase III clinical trials, including STABILITY and SOLID-TIMI 52, demonstrated that the addition of the Lp-PLA2 inhibitor darapladib to standard-of-care statin therapy did not significantly reduce the risk of cardiovascular death, myocardial infarction, or stroke (White et al., 2014; O'Donoghue et al., 2014).

Other names

PLA2G7 and HMGCRPlatelet-activating factor acetylhydrolase and HMG-CoA reductaseLp-PLA2 and HMG-CoA reductase

HMG-CoA reductase inhibitors (statins) block the conversion of HMG-CoA to mevalonate, leading to up-regulation of LDL receptors and decreased circulating LDL-C (StatPearls, 2023). Lp-PLA2 inhibitors (e.g., darapladib) specifically bind to the enzyme's active site to prevent the hydrolysis of oxidized phospholipids, thereby reducing the production of pro-inflammatory mediators like lysophosphatidylcholine and oxidized fatty acids within the arterial wall (UniProt Q13093; White et al., 2014).